Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Systemic Scleroderma
NCT06149260Phase 1Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in systemic sclerosis (SSc), sponsored by The Second Xiangya Hospital. Primary endpoint: Change in modified Rodnan Skin Score at 24 weeks. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06149260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149260.